ATP induces leukemia inhibitory factor mRNA in cultured rat astrocytes.
Leukemia inhibitory factor (LIF) is a cytokine involved in the survival and differentiation of the neural cells in the central and peripheral nervous systems. In the present study, we examined the effects of various neurotransmitter receptor agonists on LIF mRNA expression in cultured rat astrocytes, microglia and neurons to elucidate the cell types producing LIF and to clarify the neurotransmitter(s) regulating the mRNA expression. The results demonstrated that the expression of LIF mRNA was intensely induced by ATP in the cultured astrocytes. Experiments using ATP, UTP and related compounds showed the involvement of P2Y2 and P2Y4 purinoceptors in the expression induced by ATP.
Yamakuni
Hisashi
H
Department of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, 606-8501, Kyoto, Japan.
Kawaguchi
Nami
N
Ohtani
Yoshikazu
Y
Nakamura
Junji
J
Katayama
Takahiro
T
Nakagawa
Takayuki
T
Minami
Masabumi
M
Satoh
Masamichi
M
D000244:Adenosine Diphosphate / Q000378:metabolism / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D002490:Central Nervous System / Q000166:cytology / Q000254:growth & development* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005333:Fetus; D006131:Growth Inhibitors / Q000235:genetics* / Q000378:metabolism; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000235:genetics* / Q000378:metabolism; D017628:Microglia / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000494:pharmacology; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017981:Receptors, Neurotransmitter / Q000819:agonists / Q000378:metabolism*; D011983:Receptors, Purinergic / Q000187:drug effects / Q000378:metabolism*; D018048:Receptors, Purinergic P2 / Q000187:drug effects / Q000378:metabolism; D058473:Receptors, Purinergic P2Y2; D013498:Suramin / Q000494:pharmacology; D014544:Uridine Triphosphate / Q000378:metabolism / Q000494:pharmacology
D006131:Growth Inhibitors; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D018377:Neurotransmitter Agents; C546387:P2ry2 protein, rat; D012333:RNA, Messenger; D017981:Receptors, Neurotransmitter; D011983:Receptors, Purinergic; D018048:Receptors, Purinergic P2; D058473:Receptors, Purinergic P2Y2; C104749:purinoceptor P2Y4; C099845:purinoceptor P2Y6; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D014544:Uridine Triphosphate